<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04738097</url>
  </required_header>
  <id_info>
    <org_study_id>4164</org_study_id>
    <nct_id>NCT04738097</nct_id>
  </id_info>
  <brief_title>Efficacy of Ticagrelor Plus Aspirin in Minor Non-cardioembolic Ischemic Stroke</brief_title>
  <acronym>TACAMINIS</acronym>
  <official_title>Ticagrelor Plus Aspirin vs Clopidogrel Plus Aspirin in MInor Non-cardioembolic Ischemic Stroke: A Randomized, Active Comparator Arm, Outcome Assessor Blind, Conrolled, Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mazandaran University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mazandaran University of Medical Sciences</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, controlled, active comparator arm, outcome assessor blind, parallel&#xD;
      group design on 90 patient with diagnosis of ischemic stroke admitted in Bou-Ali Sina&#xD;
      Hospital, Sari,Iran.The aim of study is assess the efficacy of ticagrelor plus aspirin in&#xD;
      reduce of minor non-cardioembolic ischemic stroke or high risk TIA recurrence during first 3&#xD;
      months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, controlled, parallel, active comparator arm, outcome assessor blind,&#xD;
      feasibility study. The aim of study is assess the efficacy of ticagrelor plus aspirin in&#xD;
      reduce of minor non-cardioembolic ischemic stroke or high risk TIA recurrence during first 3&#xD;
      months after primary event. 90 patient with diagnosis of ischemic stroke admitted in Bou-Ali&#xD;
      Sina Hospital, Sari, Iran will be randomized to intervention or control group by using 4&#xD;
      block randomization method. Inclusion criteria is : age&gt;40, signing inform consent, recent&#xD;
      ischemic stroke within 24 h, diagnosed by brain CT or MRI mild stroke with NIHSS =&lt;8,high&#xD;
      risk TIA with ABCD &gt;4, no cardioembolic source such as low E/F, MS, AF ,... no specific&#xD;
      etiology such as dissection, vasculitis, ... no carotid stenosis &gt; 50 % in side of&#xD;
      involvement. Exclusion criteria is :history of hypersensitivity to consumptive drug any&#xD;
      indication for anticoagulant therapy acute phase treatment with intravenous thrombolysis or&#xD;
      thrombectomy any contraindication for consumptive drug history of intracranial hemorrhage&#xD;
      history of GI bleeding during past 6 m candidate for endarterectomy history of coagulopathy&#xD;
      active hemorrhagic diatesis during randomization. Patients in control group will be treat&#xD;
      with standard minor ischemic stroke regiment including ASA 325 mg stat and clopidogrel 300 mg&#xD;
      stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days. Intervention group will be&#xD;
      treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90&#xD;
      mg BID for 21 days. Then all groups will be treat with ASA 80 mg daily after day 21. Three&#xD;
      fallow up visit plan by a neurologist or neurology resident on month 1 and 3.Clinical data&#xD;
      including NIHSS score, MRS score and other data will record on case report form. Stroke&#xD;
      recurrence or cardiovacular event is efficacy end point. Major bleeding according to STICH&#xD;
      criteria is study safety end point. Primary outcome is ischemic stroke recurrence during&#xD;
      first 3 months after first event documented by new lesion on brain CT or MRI. Secondary&#xD;
      outcome is major hemorrhagic events, stroke recurrence during first 30 days and any&#xD;
      cardiovascular event during first 3 month.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 8, 2021</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ischemic stroke recurrence</measure>
    <time_frame>first 3 months after first event</time_frame>
    <description>recording new event based on new lesion on brain CT scan or MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major hemorrhagic event</measure>
    <time_frame>during first 30 days</time_frame>
    <description>Major bleeds were defined according to the International Society of Thrombosis and Hemostasis (ISTH)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ischemic stroke recurrence</measure>
    <time_frame>first 1 month after first event</time_frame>
    <description>recording new event based on new lesion on brain CT scan or MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>cardiovascular events</measure>
    <time_frame>during first 3 months after first event</time_frame>
    <description>any proven cardiovascular event</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Transient Ischemic Attack</condition>
  <arm_group>
    <arm_group_label>intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intervention group will be treat with ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>control gruop will be treat with ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ticagrelor 90mg</intervention_name>
    <description>ASA 325 mg stat and ticagrelor 180 mg stat, then ASA 80 mg daily and ticagrelor 90 mg BID for 21 days.Treatment will be continue with ASA 80 until 3 months.</description>
    <arm_group_label>intervention</arm_group_label>
    <other_name>Ticer</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75 mg</intervention_name>
    <description>ASA 325 mg stat and clopidogrel 300 mg stat, then ASA 80 mg and clopidogrel 75 mg daily for 21 days.Treatment will be continue with ASA 80 until 3 months.</description>
    <arm_group_label>control</arm_group_label>
    <other_name>Osvix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  signing inform consent,&#xD;
&#xD;
          -  recent ischemic stroke within 24 h,&#xD;
&#xD;
          -  diagnosed by brain CT or MRI mild stroke (non lacunar) with NIHSS =&lt;8,&#xD;
&#xD;
          -  high risk TIA with ABCD &gt;4,&#xD;
&#xD;
          -  no cardioembolic source such as low E/F, MS, AF ,...&#xD;
&#xD;
          -  no specific etiology such as dissection, vasculitis, ...&#xD;
&#xD;
          -  no carotid stenosis &gt; 50 % in side of involvement&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  history of hypersensitivity to consumptive drug&#xD;
&#xD;
          -  any indication for anticoagulant therapy&#xD;
&#xD;
          -  acute phase treatment with intravenous thrombolysis or thrombectomy&#xD;
&#xD;
          -  any contraindication for consumptive drug&#xD;
&#xD;
          -  history of intracranial hemorrhage&#xD;
&#xD;
          -  history of GI bleeding during past 6 m&#xD;
&#xD;
          -  candidate for endarterectomy&#xD;
&#xD;
          -  history of coagulopathy&#xD;
&#xD;
          -  active hemorrhagic diatesis during randomization&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Athena Sharifi-Razavi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mazandaran University of Medical science</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Athena Sharifi-Razavi</last_name>
    <phone>00989113510136</phone>
    <email>athena.sharifi@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nasim Tabrizi</last_name>
    <email>nasimtbrizi@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Athena Sharifi Razavi</name>
      <address>
        <city>Sari</city>
        <state>Mazandaran</state>
        <zip>4818777111</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>athena sharifi razavi, MD</last_name>
      <phone>00989113510136</phone>
      <email>athena.sharifi@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bou-Ali Sina hospital , Mazandarn University of Medical Science</name>
      <address>
        <city>Sari</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>athena sharifi razavi</last_name>
      <phone>00989113510136</phone>
      <email>athena.sharifi@yahoo.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>January 31, 2021</study_first_submitted>
  <study_first_submitted_qc>January 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 4, 2021</study_first_posted>
  <last_update_submitted>August 29, 2021</last_update_submitted>
  <last_update_submitted_qc>August 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mazandaran University of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Athena Sharifi Razavi</investigator_full_name>
    <investigator_title>Assistant professor in Neurology</investigator_title>
  </responsible_party>
  <keyword>minor stroke</keyword>
  <keyword>secondary prevention</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>aspirin</keyword>
  <keyword>recurrence</keyword>
  <keyword>non-cardioembolic</keyword>
  <keyword>antiplatelet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
    <mesh_term>Ischemic Attack, Transient</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD will be shared by request to principal investigator for scientifical reseasons</ipd_description>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>6 months after publishing study results</ipd_time_frame>
    <ipd_access_criteria>requested by a scientifically person, who plan for similar protocol study</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

